| No recurrence | Recurrence | ||
| Characteristic | N or Mean (%) | N or Mean (%) | p-value |
| Total patients | 65 | 7 | -- |
| Age at mastectomy | 52.5 | 57.4 | 0.26 |
| Type of cancer | |||
| DCIS | 8 (12.3) | 0 (0) | 0.33 |
| Ductal | 49 (75.4) | 7 (100) | |
| Lobular | 8 (12.3) | 0 (0) | |
| Tumor size | 0.05 | ||
| 0 - 1 cm | 10 (15.4) | 4 (57.1) | |
| 1 - 2 cm | 27 (41.5) | 1 (14.3) | |
| 2 - 5 cm | 20 (30.8) | 2 (28.6) | |
| DCIS | 8 (12.3) | 0 (0) | |
| Histologic Grade | 0.72 | ||
| 0 | 9 (13.9) | 0 (0) | |
| 1 | 11 (16.9) | 1 (14.3) | |
| 2 | 27 (41.5) | 4 (57.1) | |
| 3 | 18 (27.7) | 2 (28.6) | |
| Lymphovascular invasion (LVI) | 0.33 | ||
| Absent | 55 (84.6) | 5 (71.4) | |
| Present | 10 (15.4) | 2 (28.6) | |
| Estrogen receptor status | 0.41 1 | ||
| Negative | 18 (27.7) | 3 (42.9) | |
| Positive | 47 (72.3) | 4 (57.1) | |
| Underwent chemotherapy | 0.63 1 | ||
| No | 52 (80.0) | 5 (71.4) | |
| Yes | 13 (20.0) | 2 (28.6) | |
| Received endocrine therapy | 0.67 1 | ||
| No | 45 (69.2) | 6 (85.7) | |
| Yes | 20 (30.8) | 1 (14.3) |